[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allergic-conjunctivitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allergic-conjunctivitis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,71,103,126,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100644994","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-fel-d-1-monoclonal-antibodies-in-adult-and-pediatric-participants-with-allergic-conjunctivitis-due-to-cat-allergy-100644994",false,"NCT07675811","A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy","A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Participants With Allergic Conjunctivitis Due to Cat Allergy","Key Inclusion Criteria:\n\n1. Part A: adult participants aged 18 years and older. For part B: pediatric participants ≥8 years and \\\u003C18 years, and adult participants aged 18 years and older.\n2. Positive SPT to cat allergen extract\n3. Positive specific Immunoglobulin E (sIgE) tests for cat and Fel d 1\n4. Positive CAC criteria\n\nKey Exclusion Criteria:\n\n1. Significant and\u002For severe environmental allergies causing symptoms (eg, ocular itching, ocular redness, etc) outside of the challenge setting that are expected to coincide or may interfere with study assessments\n2. Presence of any ophthalmic disease\u002F abnormality\u002F condition that may interfere with study assessments, affect the study outcomes or participant safety\n3. A clinical history of asthma with treatment of asthma requiring systemic (oral or parenteral) corticosteroid treatment as defined in the protocol\n\nNote: Other Protocol Defined Inclusion\u002F Exclusion Criteria Apply","ALL","8 Years",{"count":19,"type":20},570,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called \"REGN-2Cat\". These medicines are also known as the \"study drugs\".\n\nThe aim of the study is to see what side effects freneslerbart, mevonlerbart, and REGN-2Cat may have and if they help reduce eye allergy symptoms caused by cat hair\u002Fdander compared with a placebo.\n\nThe study is looking at several other research questions, including:\n\n* How much study drug is in the blood at different times\n* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)\n* How long the study drug effect lasts",[26],"Allergic Conjunctivitis",[28,29,30,31,32],"Cat allergy","Eye allergy","Cat-induced eye allergy","Ocular allergy signs\u002Fsymptoms","Allergic conjunctivitis signs\u002Fsymptoms","NOT_YET_RECRUITING","2026-06-23",{"date":36,"type":37},"2026-06-30","ACTUAL",{"date":39,"type":20},"2026-07-27",{"date":41,"type":20},"2028-06-30",{"name":43,"class":44},"Regeneron Pharmaceuticals","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100616732","phase-3-study-of-bet-v1-antibodies-effect-on-eye-allergy-symptoms-in-adolescents-and-adults-with-birch-pollen-allergy-100616732","NCT07309432","Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy","A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Bet v 1 Monoclonal Antibodies in Participants With Allergic Conjunctivitis Due to Birch Pollen Allergy","Key Inclusion Criteria:\n\n1. Positive SPT to birch allergen extract\n2. Positive allergen specific Immunoglobulin E (sIgE) tests for birch and Bet v 1\n3. Positive CAC criteria\n\nKey Exclusion Criteria:\n\n1. Significant and\u002For severe environmental allergies causing symptoms (outside of the challenge setting) that are expected to interfere with study assessments\n2. Presence of any ophthalmic disease\u002Fabnormality\u002Fcondition that may interfere with study assessments, affect the study outcomes or negatively impact participant safety\n3. A clinical history of asthma with treatment of asthma requiring systemic (oral or parenteral) corticosteroid treatment more than twice within prior 12 months or once within 3 months prior to screening visit 1 or has been hospitalized or has attended the Emergency Room\u002FUrgent Care facility for asthma in the 12 months prior to screening\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria apply.","12 Years",{"count":54,"type":20},350,[23],"This study is researching 2 experimental drugs, REGN5713 and REGN5715. The study drugs will be either of these drugs given alone (either REGN5713 or REGN5715) or given together (REGN5713 and REGN5715) to reduce eye allergy signs and symptoms due to birch tree pollen allergy.\n\nThe aim of the study is to see how safe and effective the study drugs are at lowering eye allergy signs and symptoms compared with placebo.\n\nThe study will also evaluate whether the combination (REGN5713-5715) has different effectiveness than REGN5713 or REGN5715 alone.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drugs\n* How much of the study drugs is in the blood at different times\n* Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)",[26],[59,60,61],"Birch Pollen Allergy","Ocular allergy symptoms","Ocular allergy signs","RECRUITING","2026-06-22",{"date":34,"type":37},{"date":66,"type":37},"2026-01-10",{"date":68,"type":20},"2027-06-15",{"name":43,"class":44},2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":70},"100377761","proteomic-and-metabolomic-lacrimal-fingerprint-in-diverse-pathologies-of-the-ocular-surface-100377761","NCT04198740","Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface","EML-MSO","Inclusion Criteria:\n\n* Patients with healthy corneas or suffering from one of these pathologies:\n\nDry eye syndrome; Infectious keratitis and\u002For conjunctivitis; Mucous membrane pemphigoid; Allergic conjunctivitis.\n\nExclusion Criteria:\n\n* Patients younger than 18 years old;\n* Patients incapable of giving informed consent.",true,"18 Years",{"count":81,"type":20},300,"OBSERVATIONAL","This study aims to obtain the lacrimal fingerprint for frequent pathologies of the ocular surface and establish a normative base for each of them.",[85,86,87,26],"Dry Eye Syndrome","Infectious Keratoconjunctivitis","Mucous Membrane Pemphigoid",[89,90,91,92],"Lacrimal fingerprint","Metabolomics","Proteomics","Ocular surface","2026-04-23",{"date":95,"type":37},"2026-04-27",{"date":97,"type":37},"2020-02-01",{"date":99,"type":20},"2035-01",{"name":101,"class":102},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100609886","phase-2-evaluation-of-tl-925-for-the-treatment-of-seasonal-allergic-conjunctivitis-100609886","NCT07220408","Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis","A Single Center, Randomized, Double-masked, Vehicle Controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Seasonal Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model","Inclusion Criteria:\n\n* Individuals aged 18 years or older\n* Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.\n* Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.\n* Calculated best-corrected visual activity\n* Positive bilateral CAC reaction\n\nExclusion Criteria:\n\n* Any systemic or ocular disease currently producing ocular redness and\u002For ocular discomfort, or that may interfere with the conduct of the study.\n* Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months\n* Any ongoing ocular infection (bacterial, viral or fungal)",{"count":111,"type":20},60,[113],"PHASE2","In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.\n\nThe study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.",[26],"2025-11-22",{"date":118,"type":37},"2025-11-25",{"date":120,"type":37},"2025-10-23",{"date":122,"type":20},"2026-02",{"name":124,"class":44},"Telios Pharma, Inc.",1,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":78,"sex":16,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":125},"100551371","factors-determining-tolerance-to-nasal-allergen-exposure-with-advanced-age-in-a-subset-of-birch-pollen-allergic-subjects-100551371","NCT06459219","Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects","AllergyAge","Inclusion Criteria:\n\n* General inclusion criteria Age ≥ 60 years Willingness to participate in the study and to follow the protocol Written informed consent Standard healthcare insurance Subjects should be available during the entire study period\n* Patient group specific inclusion criteria (n=38 per group):\n\n  1. Group 1 (current allergy):\n\n     Ongoing intermittent allergic rhinoconjunctivitis to birch pollen with moderate to severe symptoms according to ARIA guidelines for at least 10 years Positive Skin prick test (SPT) to birch pollen and\u002For Bet v 1-specific IgE ≥0.35kUA\u002FL as measured by ImmunoCAP\n  2. Group 2 (former allergy):\n\n     History of intermittent allergic rhinoconjunctivitis to birch pollen ongoing with moderate to severe symptoms according ARIA guidelines for at least ten years (verified by at least one medical record including SPT results), but no symptoms for at least the three past consecutive seasons Positive or negative SPT to birch pollen and Bet v 1-specific IgE ≤ or ≥0.35kUA\u002FL as measured by ImmunoCAP\n  3. Group 3 (never allergy):\n\nNo history of and no ongoing allergic rhinoconjunctivitis to birch pollen Negative SPT to birch pollen and Bet v 1-specific IgE ≤ 0.35kUA\u002F\n\nExclusion Criteria:\n\n* \\- Evidence of acute, chronic, malignant or general diseases-assessed by asking the patient\n* A History of anaphylaxis\n* Utilization of leukotriene modifiers or long-acting antihistamines\n* Chronic or intermittent use of oral, inhaled, intramuscular or intravenous corticosteroids\n* Nasal polyps, history of chronic sinusitis or considerable deviation of the nasal septum\n* Rhinitis secondary to other causes\n* Contra-indications to skin prick testing, for example, skin irritation in the test area and urticaria facticia\n* Cardiovascular diseases requiring treatment with anti-hypertensive medication or beta-blockers\n* Known clotting disorders\n* Chronic use of additional medications that would affect assessment and the results of the study (e.g., tricyclic antidepressants that block both H1 and H2 receptors)\n* Pregnant or breastfeeding females\n* Actual disability that would influence subject's ability to participate in the study\n* History of mental illness, intellectual deficiency, drug or alcohol abuse\n* Active asthma requiring treatment\n* Allergen immunotherapy within the last 5 years to any allergen\n* Current and former smokers who stopped smoking \\\u003C1 year ago","60 Years",{"count":135,"type":20},152,"Nasal allergen study in patients aged 60+ with or without current respiratory allergy",[138,26],"Allergic Rhinitis","2025-05-06",{"date":141,"type":37},"2025-05-07",{"date":143,"type":20},"2025-12-01",{"date":145,"type":20},"2028-10-01",{"name":147,"class":102},"Sven Schneider, MD",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":125},"100568841","phase-2-evaluation-of-tl-925-for-the-treatment-of-allergic-conjunctivitis-100568841","NCT06686472","Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis","A Single-Center, Randomized, Double-masked, Vehicle-controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model","Inclusion Criteria:\n\n* Individuals aged 18 years or older\n* Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.\n* Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.\n* Calculated best-corrected visual activity of 0.7 LogMAR or better\n* Positive bilateral CAC reaction\n\nExclusion Criteria:\n\n* Any systemic or ocular disease currently producing ocular redness and\u002For ocular discomfort, or that may interfere with the conduct of the study.\n* Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months\n* Any ongoing ocular infection (bacterial, viral or fungal)",{"count":156,"type":20},66,[113],"In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.\n\nThe study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.",[26],"2024-11-11",{"date":162,"type":37},"2024-11-13",{"date":164,"type":37},"2024-10-03",{"date":166,"type":20},"2024-12-10",{"name":124,"class":44}]